Botox (botulinum toxin) is widely marketed for aesthetic enhancement and medical indications including migraines and hyperhidrosis. Emerging evidence suggests it may have systemic effects on muscle metabolism, joint stability, and overall musculoskeletal health. The therapy has helped millions, and there are uses I still value. But the less-discussed effects, and the case for more careful patient screening — especially in populations at higher risk for joint instability, sarcopenia, or osteopenia — are worth taking seriously.
Case Update: Systemic Effects of Botox in Ehlers-Danlos Syndrome
A personal exploration: Botox and muscle recovery
At TOBI 2024, Dr. Rowan Paul and I presented Orthobiologics in Ehlers-Danlos Syndrome: A Transformative Case Report. Previous discussions focused on connective tissue vulnerabilities and orthobiologic approaches. This year’s update introduces a new variable: Botox use. For the first time, we explore how long-term Botox use may contribute to systemic muscle suppression, metabolic disruption, and broader implications for patient management.
The patient (myself), a 36-year-old woman with hEDS, multiple variants of unknown significance in collagen-related genes (COL5A2: c.1633C>T; COL4A4: c.3979G>A; COL17A1: c.4304C>T, p.A1435V), and variants in transcobalamin, methionine synthase, MTHFR (compound heterozygous), and glutathione synthase, had a 15-year history of approximately 20 units of Botox in the forehead and glabellar lines every 4–6 months. Initially prescribed for tension headaches during medical school exams, then continued for aesthetic purposes, Botox was discontinued during recovery from a rotator cuff tear (sustained the day before TOBI 2024).
The results were transformative. Hip abduction strength nearly doubled, from 90–100 lbs to 180 lbs. For the first time in adult memory I could perform unassisted pull-ups. I also observed increased quadriceps mass and notable lat prominence — improvements consistent with the inverse correlation between leg strength and all-cause mortality (BMJ). My facial structure changed as the masseter — never directly injected — regained prominence. That suggests systemic diffusion of Botox may have suppressed muscle activation beyond the injection site, and could have contributed to atlantoaxial instability.
Emerging literature supports the hypothesis. Botulinum toxin can produce systemic muscle effects distant from the injection site (Crowner et al. 2010, Clin Neuropharmacol — a case series at high cumulative doses), and intramuscular Botox injection has been shown to cause tendon atrophy via senescence of tendon-derived stem cells in preclinical models (Chen et al. 2021, Stem Cell Res Ther). This aligns with the substantial strength recovery and increased exercise capacity I observed post-cessation — findings relevant to all patients but especially to EDS patients, who already have connective tissue fragility.
This is one person’s experience, framed clearly as such. The mechanism is plausible and the literature is suggestive. But this is a case report, not a clinical trial. The takeaway worth generalizing is the screening recommendation, not the magnitude of effect.
Systemic Absorption and Metabolic Effects: A Growing Hypothesis
Although Botox is marketed as a localized treatment, studies suggest it can be absorbed systemically with cumulative effects, some of which may be permanent. Research in Clinical Neuropharmacology (Crowner et al. 2010, PMID 20852412) describes systemic weakness distant from the injection site. Even light use — such as my 20 units in the forehead — may influence muscle tone, metabolism, and stem cell activity in tendons. Patients today are marketed Botox for hyperhidrosis, lip flips, forehead wrinkle prevention, headache treatment, masseter slimming (“V-Line Tox”), and trap-tox (“Barbie Tox”) — regions and dosages often larger than those in the cited studies.
More recently, approximately 25 units of hyperdilute Botox was incorporated into my last three cycles of bilateral stellate ganglion blocks. The blocks were undeniably helpful, and I’d still consider intermittent use in that setting valuable when done with informed consent and as part of a holistic picture. Given my current stability, I’d omit the hyperdilute Botox from further stellate blocks, but I still value its prior use and would consider intermittent future use if warranted.
A working hypothesis worth flagging clearly: patients with connective tissue disorders such as EDS may have increased susceptibility to Botox diffusion due to altered extracellular matrix composition, vascular permeability, or neuromuscular signaling. That could make them more prone to systemic effects, unintended muscle weakening, or prolonged impact beyond the injection site. This is a hypothesis to investigate, not an established mechanism.
Side Effects: What the Research Shows
Botulinum toxin injections can lead to tendon atrophy by inducing senescence in tendon-derived stem cells (TDSCs), which may result in long-term musculoskeletal effects including reduced tendon strength and impaired healing (Stem Cell Research & Therapy).
BTX injections can lead to muscle atrophy and subsequent bone loss, particularly in populations at risk such as postmenopausal women or individuals with chronic illness. Animal studies have demonstrated this: one rat study reported a 61% decrease in rectus femoris muscle mass and a 31% reduction in femoral neck bone strength after BTX injection (Springer).
Research has also shown BTX-induced muscle atrophy contributing to bone loss in both the injected and contralateral limbs, even at dosages used in masseter and trapezius injections. A mouse study found BTX injections produced significant muscle atrophy and bone loss in the treated limb and the untreated contralateral limb — suggesting systemic effects (Springer). The same pattern appears in patients treated for spasticity; proposed mechanisms include systemic toxin spread or neural adaptations producing bilateral muscle weakening. A study on post-stroke spasticity management reported contralateral weakness and fatigue following high-dose BoNT-A injections (J Neurology).
These findings highlight the potential impact of BoNT-A injections beyond the targeted muscles — relevant for both therapeutic and aesthetic applications where muscle integrity and joint stability matter.
Implications for Joint Stability
Weakening of both targeted and contralateral muscles has implications for joint stability. Muscles maintain joint integrity, so their atrophy may predispose to joint instability and complications. This is particularly relevant for commonly injected muscles like the trapezius and masseter, targeted in aesthetic procedures (“traptox,” “v-line tox,” “barbietox”). Weakening these muscles could affect stability of the shoulder girdle, craniocervical junction, and temporomandibular joint.
Botox and Potential Metabolic Suppression
Botox’s ability to suppress muscle activity may also suppress metabolism. Over time, this may contribute to “skinny-fat” body composition — low muscle mass, normal or slightly elevated body fat, metabolic dysfunction — sometimes presenting with osteopenia. The concern compounds with the rising popularity of GLP-1 agonists like semaglutide, now widely marketed off-label. These drugs slow digestion and may further reduce metabolism, potentially compounding sarcopenia and osteopenia risk in aging populations.
The Alzheimer’s connection: my working hypothesis, not established fact
I want to flag the following as my working hypothesis, not established science.
Metabolic health, particularly muscle mass, plays a role in mitigating Alzheimer’s risk. Alzheimer’s is sometimes referred to as “type 3 diabetes” because of its association with insulin resistance (U.S. News Health, Harvard Health). My hypothesis is that a global, prolonged reduction in muscle mass during key muscle and bone maintenance years could theoretically provoke increased Alzheimer’s risk by impairing systemic metabolic regulation. This has not been demonstrated for Botox specifically. It’s a chain of plausible mechanisms — Botox → muscle suppression → metabolic dysfunction → insulin resistance → cognitive risk — none of which has been studied as a connected pathway.
The supporting literature on the individual links: insulin sensitivity matters for glucose uptake in the hippocampus, and impaired insulin signaling there can decrease neuroplasticity and produce cognitive deficits (Diabetes Journals). Insulin plays a role in hippocampal memory formation; systemic insulin resistance can interfere with hippocampal metabolism and cognition (Oxford Academic).
If this hypothesis holds, the population most at risk is patients with family history of Alzheimer’s, APOE ε4 carriers, and patients with comorbidities such as MCAS who require essential antihistamine medications. Anticholinergic antihistamines like diphenhydramine are independently associated with increased dementia risk (Harvard). For MCAS patients who depend on those medications, the question of layering additional metabolic suppression deserves serious thought.
The Botox generation hasn’t yet reached old age. Long-term effects of widespread, sustained botulinum toxin use on metabolic and cognitive health remain unknown.
Updated Recommendations for Screening
Patient evaluations should incorporate Botox history, particularly for patients at higher risk for musculoskeletal or metabolic complications.
Joint instability and connective tissue disorders
Patients with EDS, generalized hypermobility, or other connective tissue disorders should be assessed for Botox use, which may exacerbate existing muscle weakness and contribute to joint instability.
Muscle mass and metabolic health
- Screen for sarcopenia and osteopenia in patients with regular, high-dose, or long-term Botox use — especially those also using metabolic suppressors like GLP-1 agonists (semaglutide, liraglutide).
- Evaluate patients with low muscle mass or chronic illness for compounded risks: accelerated muscle loss, metabolic slowdown, reduced functional strength.
Rehabilitation and injury recovery
- Patients recovering from orthopedic injuries should be informed of potential systemic Botox effects, which may impair muscle recovery, slow strength gains, or exacerbate instability.
- Potential for accelerated arthritis from muscle weakening and joint instability should also be considered.
- Potential neurological effects warrant further investigation.
Neurodegenerative disease risk and fall prevention
- Patients with family history of Alzheimer’s or increased neurodegeneration risk should be screened for long-term Botox use. Emerging research suggests potential links between Botox, metabolic dysfunction, and cognitive decline — these are not yet clear.
- Patients at fall risk should be evaluated for Botox-related muscle weakening that could affect balance and mobility.
Regulatory and Safety Considerations
The CDC is investigating Botox safety concerns, including reports of neurological side effects — some of which may not be solely due to counterfeit products (CDC Botox Safety Inquiry).
Given the growing body of evidence, clinicians should prioritize informed consent, patient education, and proactive screening for safe and responsible administration — particularly for high-risk populations.
Conclusion: A More Cautious Approach
Botox has real benefits, and there are settings where the benefit outweighs the risk — intermittent or low-frequency use during focused rehabilitation for cerebral palsy, and the off-label hyperdilute use in stellate ganglion blocks for CPSD treatment. The systemic and long-term effects warrant greater scrutiny. For patients with musculoskeletal concerns, injuries, or risk for sarcopenia, osteopenia, or metabolic dysfunction, the risks may outweigh the benefits. More research is needed on long-term implications for metabolism, muscle strength, and overall health — and on the combination with GLP-1 agonists. Until then, prioritize patient education, thorough screening, and informed consent.
Read more about management of Ehlers-Danlos syndrome here.